Health Technology Assessment of Belimumab: A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus

Table 4

Base case results (NHS perspective).

	SoC	Belimumab	Difference
Life years	18.99	19.76	0.77
QALYs	10.78	11.31	0.538
Costs	€125,234	€142,921	€17,688
ICUR			€32,859
ICER			€22,990

SoC: standard of care; QALY: quality adjusted life year; ICUR: incremental cost-utility ratio; ICER: incremental cost-effectiveness ratio.